IP Library Granted Patent US 9,254,280
Granted Patent B2
US 9,254,280 · App. 14/118,187 · Granted Feb 9, 2016

Medical food for cognitive decline

Inventors: Gregory M. Cole (Santa Monica, CA); Sally A. Frautschy (Santa Monica, CA); David R. Schubert (La Jolla, CA); Pamela A. Maher (La Jolla, CA)
Assignees: The Regents of the University of California; Salk Institute for Biological Studies; U.S. Department of Veterans Affairs
A61K31/353A23L1/3002A23L1/3008A61K31/202A61K31/352A23V2002/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,254,280
App. No.
14/118,187
Granted
Feb 9, 2016
Kind
B2
Abstract

Nutraceutical formulations that improve cognitive function in adults diagnosed with neurodegenerative disease are provided, which comprise a combination of fisetin and DHA.

Claims (16)

1. A composition comprising a synergistic combined amount of fisetin and docosahexaenoic acid (DHA) in a ratio effective in reducing cognitive defects.

2. The composition of claim 1 , wherein the ratio of fisetin to DHA by weight is from about 1:20 to 20:1.

3. The composition of claim 2 , wherein the ratio of fisetin to DHA by weight is from about 1:1 to 1:20.

4. The composition of claim 3 , wherein the ratio of fisetin to DHA by weight is from about 1:5 to 1:20.

5. The composition of claim 4 , wherein the composition comprises at least 500 mg DHA.

6. A unit dose composition comprising a synergistic combined amount of fisetin and docosahexaenoic acid (DHA) effective in reducing cognitive defects, in a dose comprising at least about 1 g. DHA; and wherein the ratio of DHA to fisetin by weight is from about 1:2 to 1:10.

7. The composition of claim 6 , wherein the composition comprises at least about 5 g. DHA.

8. The composition of claim 1 , wherein the composition consists essentially of fisetin and DHA.

9. The composition of claim 1 , wherein the composition is a dietary supplement.

10. The composition of claim 1 , wherein the composition is formulated for administration to a subject.

11. The composition of claim 1 , wherein the composition is formulated for use as a food additive.

12. The composition of claim 1 , wherein the composition is formulated as a liquid.

13. A method of improving cognitive performance in a subject, the method comprising administering a composition according to claim 6 .

14. The method of claim 13 , wherein the subject suffers from a neurodegenerative disorder.

15. The method of claim 14 , wherein the neurodegenerative disorder is Alzheimer's disease.

16. The method of claim 13 , wherein the formulation is administered orally.

Assignments (3)
CONFIRMATORY LICENSE Recorded Jul 27, 2015
From: UNIVERSITY OF CALIFORNIA LOS ANGELES
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 036191/0505 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 6, 2014
From: COLE, GREG M.; FRAUTSCHY, SALLY A.
To: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA; DEPARTMENT OF VETERANS AFFAIRS
Reel/Frame 033051/0498 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 6, 2014
From: SCHUBERT, DAVID; MAHER, PAMELA
To: SALK INSTITUTE FOR BIOLOGICAL STUDIES
Reel/Frame 033051/0512 →
Continuity (2)
Provisional Application 61488003 · May 19, 2011
Related Publication 20140142172A1 · May 22, 2014